Skip to main content

Month: May 2023

Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH

12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?” 15 of 16 voting-eligible advisors vote to “defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered” PDUFA Target Action Date set for June 22, 2023 Company to host conference call on Monday, May 22, 2023, at 8:30 a.m. ET MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug...

Continue reading

VERSES Announces Proposed Warrant Amendment

VANCOUVER, British Columbia, May 19, 2023 (GLOBE NEWSWIRE) — VERSES AI Inc. (NEO:VERS) (“VERSES” or the “Company”), a cognitive computing company specializing in next generation Artificial Intelligence, announces its plan to amend certain terms of an aggregate of 1,316,787 Class A subordinate voting share purchase warrants, which were issued as consideration to certain arm’s length finders (the “Finder Warrants”) as consideration for the introduction of certain subscribers to the Company in connection with its private placement offering of 20,000,000 special warrants (“Special Warrants”) at an issue price of $0.80 per Special Warrant for aggregate gross proceeds of $16,000,000, which completed in two tranches on October 21, 2021 and November 2, 2021. Each Finder Warrant is exercisable at an issue price of $0.80...

Continue reading

Autoscope Technologies Corporation Dividend Payment

MINNEAPOLIS, May 19, 2023 (GLOBE NEWSWIRE) — Autoscope Technologies Corporation (OTCQX: AATC) today announced that the Board of Directors declared a dividend of $0.26 per share payable to shareholders of record as of May 30, 2023 with payment expected on or about June 6, 2023. This includes a payment of $0.13 per share for the 2023 first quarter dividend, which was delayed by the late filing of the Company’s 2022 Annual Report, including its audited financial statements, as well as an additional $0.13 per share for the current quarter. Executive Chair Andrew Berger said, “The Board is pleased to resume the payment of dividends now that the Company has successfully transitioned to the OTCQX Best Market platform. The Company increased its quarterly dividend from $0.12 per share to $0.13 per share and is now current on its commitment...

Continue reading

Carter Glatt to be Chairman Nominee of Global Hydrogen Energy LLC’s Post-Closing Board

Global Hydrogen is a Pure Play Hydrogen and Carbon Recovery Project Developer and Industrial Gas Supplier WEST PALM BEACH, Fla. & NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) — Global Hydrogen Energy LLC (“Global Hydrogen”), which seeks to be a leader in the sustainable energy transition as a next-generation industrial gas supplier, today announced that Carter Glatt, CEO and Director of Dune Acquisition Corporation (Nasdaq: DUNEU, DUNE, DUNEW) (“Dune”), will serve as Chairman Nominee of its post-closing Board. On May 15, 2023, Dune, a special purpose acquisition company, and Global Hydrogen announced that they have entered into a definitive agreement for a business combination, which would result in Global Hydrogen becoming a publicly listed company.  The combined company will be called Global Gas Corporation upon the closing...

Continue reading

Creative Realities Rejects Unsolicited Proposal by Pegasus Capital Advisors, L.P.

LOUISVILLE, Ky., May 19, 2023 (GLOBE NEWSWIRE) — As previously reported, on May 1, 2023, Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX, CREXW) received a revised proposal (the “Revised Proposal”) from Pegasus Capital Advisors, L.P., on behalf of itself and certain of its affiliates (collectively, “Pegasus”), to acquire all of the outstanding shares of common stock of the Company that are not owned by Pegasus for a purchase price of $2.85 per share in cash. The Revised Proposal followed an earlier proposal (the “Original Proposal”) from Pegasus to acquire all of the outstanding shares of common stock of the Company that are not owned by Pegasus for a purchase price of $2.49 per share in cash (adjusted for the Company’s 1-for-3 reverse stock split) effected March 27, 2023. The Original Proposal...

Continue reading

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased bladder capacity versus placebo, and improved quality of life1PARIS, FRANCE, 9 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who are regularly performing clean intermittent catheterization (CIC). This positive opinion for Dysport® now permits individual European country Health Authorities to grant national approvals, according to...

Continue reading

MCI Onehealth to Sell Operations in Alberta to WELL Health for $2 Million

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 19, 2023 (GLOBE NEWSWIRE) — MCI Onehealth Technologies Inc. (“MCI” or the “Company”) (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, today announced that it has entered into a definitive agreement with WELL Health Technologies Corp. (“WELL”) for the sale of its operations in Alberta, including its five MCI The Doctor’s Office medical clinics, for a purchase price of $2 million (the “Transaction”). “This transaction will help support the operational needs of MCI Onehealth in the short- to medium-term, while preserving quality care for our loyal patient population by placing our Alberta clinics into the hands of an innovative, tech-forward Canadian healthcare leader...

Continue reading

Form 8.3 – [EMIS Group plc – 18 05 2023] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias

Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI)Preservation of raw unipolar signal using BioSig’s PURE EP™ platform guidance enabled real-time tissue-specific feedback when conducting ablationCleveland, OH and Westport, CT, May 19, 2023 (GLOBE NEWSWIRE) — Researchers from Cleveland Clinic will be presenting data from three abstracts at Heart Rhythm 2023 that evaluated an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI)—a type of ablation procedure used to treat atrial fibrillation (AF)—compared to the existing standard, the Ablation Index™. Researchers used BioSig Technologies, Inc. (NASDAQ: BSGM) proprietary PURE EP™ Platform for real-time tissue-specific feedback to achieve equal lesion...

Continue reading

Gulf & Pacific Equities Corp. reports on First Quarter Results with Revenue of $975,248 And Completes Additional Financing

Toronto, ON, May 19, 2023 (GLOBE NEWSWIRE) — Gulf & Pacific Equities Corp. (TSX-V: GUF) an established company focused on the acquisition, management and development of anchored shopping centres in Western Canada, reports a 3.7% increase in revenues to $975,248 in the quarter ended March 31, 2023, from $940,004 at the same period last year. Details of the three months financial results for fiscal 2023 and 2022 under International Financial Reporting Standards (IFRS), as summarized below, are also available at www.sedar.com or the company’s website www.gpequities.com.    Three Months Ended    (Unaudited)    March 31,      2023     2022         Revenue   $ 975,248   $ 940,004         Net Income (Loss) before fair value adjustment,      other income items and income taxes   $ (62,043 ) $    (74,684 )Net...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.